Navigation Links
PK Study Comparing Upsher-Smith's Extended-Release Topiramate Formulation (USL255) With Topamax® Published Online In Epilepsia
Date:7/25/2011

MAPLE GROVE, Minn., July 25, 2011 /PRNewswire/ -- In a comparative pharmacokinetic (PK) study, Upsher-Smith Laboratories' USL255, a new, once-daily extended-release formulation of topiramate in development for the management of epilepsy in adults, was shown to be bioequivalent to twice-daily immediate-release topiramate (Topamax®*) in its extent of absorption.  Furthermore, USL255, administered with or without food, demonstrated a slower absorption profile compared with Topamax®.  The more consistent plasma profile of USL255 allows for once-daily dosing with diminished fluctuations in topiramate plasma levels.  The results of this study were published in the online edition of Epilepsia on July 20, 2011.

"In the study, this new topiramate extended-release formulation demonstrated less fluctuation between the peak and trough concentrations than immediate-release topiramate; thereby providing a relatively flat topiramate plasma concentration versus time profile that should allow for once-daily dosing.  Once-daily dosing may simplify topiramate therapy in adult epilepsy patients," said Larry Lambrecht, Pharm.D., first author.  "In theory, reducing fluctuations of plasma concentrations of antiepileptic drugs may also minimize potential concentration-related adverse events."

About the PK StudyThe randomized, open-label, cross-over study had three dosing periods separated by 21 days of washout between treatments. Thirty-six healthy adult volunteers received single doses of USL255 (200 mg) in fasted and fed conditions and two doses of Topamax® (100 mg) administered 12 hours apart. Topiramate plasma samples were analyzed by liquid chromatography with tandem-mass spectroscopy.  

A single dose of USL255 was found to be bioequivalent to Topamax® in its extent of absorption; however, it had a slower extent of absorption as reflected by its later t(max) (time to reach peak plasma concentration) and t(1/2,eff) (effective half-life) values.  A median t(max) value of 20 and 24 hours after single dose indicates that topiramate absorption will continue throughout the 24-hour dosing interval in both fasted and fed conditions, respectively.  The plateau time (the time span in which topiramate plasma concentrations deviated from C(max) by less than 20%) of USL255 was three to four times longer than that of Topamax®.  

Mean +/- SD PK parameters of topiramate following a single dose of USL255 (200 mg) with or without food and Topamax® (100mg Q12h)PK ParameterUSL255 (fasted)N=35USL255 (fed)N=36Topamax®N=35t(max) (h)

Mean

Median19.5+/- 7.2

2022.7 +/- 4.3

241.4 +/- 1.1

1Effective half-life

t(1/2, eff) (h)55.7 +/- 19.972.5 +/- 15.437.1 +/- 6.5Plateau Time

12.1 +/- 4.0

8.0 +/- 3.3

2.6 +/- 1.9C(max)/C(trough)1.2 +/- 0.11.1 +/- 0.11.7 +/- 0.3USL255 is also the subject of an ongoing large, global Phase III clinical trial (PREVAIL) in which Upsher-Smith expects to demonstrate that it is effective and well-tolerated as adjunctive therapy in adult epilepsy patients with refractory partial-onset seizures.  Currently, patients completing the PREVAIL study are eligible to enroll in an open-label extension study to provide extended therapy and to capture additional long-term tolerability information.  Further information on the PREVAIL and open-label extension studies can be found at http://clinicaltrials.gov/ct2/show/NCT01142193?intr=%22USL255%22&rank=1; http://clinicaltrials.gov/ct2/show/NCT01191086?intr=%22USL255%22&rank=2  respectively.

About EpilepsyEpilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions.  An estimated three million people in the U.S. have some form of epilepsy with about 200,000 new cases of epilepsy diagnosed each year.(1)

Upsher-Smith's Expanding CNS PipelineUpsher-Smith's central nervous system (CNS) pipeline includes a number of investigational drug programs.  In addition to USL255 (extended-release topiramate), USL is developing an intranasal midazolam (USL261), for the rescue treatment of seizures in patients on stable anti-epileptic drug regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters.  Another program is USL260 (tonabersat), an investigational drug and first-in-class neuronal gap junction modulator which is also a potential treatment for epilepsy.  

About Upsher-SmithUpsher-Smith Laboratories, Inc., founded in 1919, is a rapidly growing, privately held pharmaceutical company that develops, manufactures, and markets prescription and consumer products.  Upsher-Smith's product portfolio focuses in the areas of women's health, dermatology, cardiology, and CNS diseases.  The company's focus is growing a CNS pipeline for diseases with significant unmet need, including epilepsy and Parkinson's disease.  To expand its CNS pipeline, Upsher-Smith seeks alliances and co-development programs, pursues licensing and acquisitions, and leverages its core competency in formulation development.  For more information, visit www.upsher-smith.com.

*Topamax® (immediate-release topiramate) is a registered trademark of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals.

References(1) Epilepsy Foundation. Epilepsy and seizure statistics. Available at: http://www.epilepsyfoundation.org/about/statistics.cfm. Accessed May 18, 2011.


'/>"/>

SOURCE Upsher-Smith
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Proves McDavid Ankle Braces Significantly Prevent Injuries
2. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
3. Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
4. Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
5. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
6. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
7. Bayer Study Reveals Gaps in Perception of Veterinary Care Between Vets and Pet Owners
8. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
9. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
10. Exenatide tQT Study Showed No Prolongation of QT Interval
11. PicoCal Inc. Announces Completion of NSF Funded Research With a Number of New Products, Patents, Publications of Innovative Devices for Topographical Imaging, Thermomechanical Analysis, the Study of Local Mechanical Properties and High Throughput Ap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):